ALK and non-small cell lung carcinoma: CNS metastases can lead to substantial morbidity and decrease the quality of life.8 The management strategies for CNS metastases mainly rely on local therapies (surgery, whole-brain radiotherapy, and stereotactic radiosurgery), but the advent of small-molecule systemic therapies which can cross the blood-brain barrier has improved the prognosis of NSCLC patients with CNS involvement, including those with ALK-positive NSCLC.9